This marks a significant milestone in the company’s global expansion of its most advanced portable MRI technology, supporting international commercial growth and improving global access to high-quality brain imaging at the point of care.

Following CE mark and UKCA approval, the next-generation Swoop® system, also known as Model 2, is now commercially available across an initial wave of European markets.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.